Slaughter and May and Hogan Lovells are advising GlaxoSmithKline (GSK) and Google parent company Alphabet on the creation of a company that will design technology to combat disease with electrical signals.

Verily Life Sciences (formerly Google Life Sciences), an Alphabet company, and pharmaceutical giant GSK will contribute up to £540m during the next seven years to new joint venture Galvani Bioelectronics. The new company will be headquartered in the UK.

The Slaughters team includes corporate partners Susie Middlemiss and David Johnson, tax partner Dominic Robertson and competition partner Bertrand Louveaux.

Hogan Lovells is advising Alphabet.

In March last year, Slaughters advised GSK on the sale of half its stake in South African drug maker Aspen for $853m (£574m).

That London-based team was led by Johnson and Robertson.

The firm also advised GSK in February 2015, when it sold its 7.9% stake in Danish biotech company Genmab to institutional investors.

Earlier this year, GSK was hit with a £37.6m fine by the Competition and Markets Authority for paying rival drug makers to delay the release of their competing drugs into the UK marketplace between 2001 and 2004.

Nabarro advised GSK with a team led by competition partner Brian Sher. The firm also instructed Brick Court Chambers' James Flynn QC on the case and was supported by economist Charles River Associates.

Cleary Gottlieb Steen & Hamilton landed the lead role advising Google on its major restructuring, which led to the creation of Alphabet in August last year.